Phase 2 study of dasatinib in Chinese patients with chronic myeloid leukemia (CML) in chronic phase (CP) or advanced phase who are resistant to or intolerant of imatinib (IM)

被引：0
|
作者：
Wang, Jianxiang [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ]
Huang, Xiaojun
Hu, Jianda
Li, Jianyong
Jin, Jie
Meng, Fanyi
Shen, Zhixiang
Liu, Ting
Wu, Depei
Wang, Jianmin
机构：
[1] Chinese Acad Med Sci, Inst Hematol, Beijing, Peoples R China
[2] Chinese Acad Med Sci, Blood Dis Hosp, Beijing, Peoples R China
[3] Peking Univ, Inst Hematol, Beijing, Peoples R China
[4] Peking Univ, Peoples Hosp, Beijing, Peoples R China
[5] Fujian Med Univ, Union Hosp, Fuzhou, Peoples R China
[6] Fujian Med Univ, Union Hosp, Fuzhou, Peoples R China
[7] Jiangsu Prov Hosp, Suzhou, Peoples R China
[8] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China
[9] Southern Med Univ, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China
[10] Shanghai Jiao Tong Univ, Shanghai Ruijin Hosp, Shanghai, Peoples R China
[11] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
[12] Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China
[13] Second Mil Med Univ, Changhai Hosp, Shanghai, Peoples R China
来源：
LEUKEMIA & LYMPHOMA | 2013年 / 54卷
关键词：
CML; dasatinib; imatinib-resistance;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3
引用
收藏
页码：3 / +
页数：3
相关论文
共 50 条
  • [31] Molecular Responses to Dasatinib and Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
    Quintas-Cardama, Alfonso
    Kantarjian, Hagop
    Michor, Franziska
    Olshen, Adam
    Gonen, Mithat
    Jones, Dan
    Rios, Mary Beth
    O'Brien, Susan
    Cortes, Jorge
    BLOOD, 2008, 112 (11) : 1114 - 1115
  • [32] Results of a Phase II Trial of Dasatinib As Frontline Therapy for Chronic Myeloid Leukemia (CML) In Chronic Phase (CP)
    Pemmaraju, Naveen
    Kantarjian, Hagop M.
    Luthra, Rajyalakshmi
    O'Brien, Susan
    Jabbour, Elias
    Quintas-Cardama, Alfonso
    Borthakur, Gautam
    Ravandi, Farhad
    Verstovsek, Srdan
    Burton, Elizabeth
    Walker, Brenda
    Cortes, Jorge E.
    BLOOD, 2011, 118 (21) : 740 - 741
  • [33] Minimal Cross-Intolerance Between Nilotinib and Imatinib in Patients with Imatinib-Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) or Accelerated Phase (CML-AP)
    Jabbour, Elias
    Kantarjian, Hagop M.
    Baccarani, Michele
    de Coutre, Philipp D.
    Haque, Ariful
    Gallagher, Neil J.
    Cortes, Jorge
    Giles, Francis
    BLOOD, 2008, 112 (11) : 1103 - 1103
  • [34] A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib-resistant and -intolerant patients with chronic myelogenous leukemia (CML) in chronic phase (CP).
    le Coutre, Philipp
    Bhalla, Kapil
    Giles, Francis
    Baccarani, Michele
    Ossenkoppele, Gert J.
    Hochhaus, Andreas
    Gattermann, Norbert
    Rafferty, Teresa
    Haque, Ariful
    Weitzman, Aaron
    Kantarjian, Hagop
    BLOOD, 2006, 108 (11) : 53A - 53A
  • [35] Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia
    Khoury, Hanna J.
    Goldberg, Stuart L.
    Mauro, Michael J.
    Stone, Richard M.
    Deininger, Michael W.
    Bradley-Garelik, M. Brigid
    Mohamed, Hesham
    Guilhot, Francois
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (06): : 341 - +
  • [36] Grade 3/4 adverse events in imatinib resistant/intolerant chronic phase CML (CML-CP) patients treated with nilotiniband dasatinib
    Stephens, J.
    Carpiuc, K. T.
    Snedecor, S. J.
    Botteman, M. F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 205 - 206
  • [37] Dasatinib lack of cross intolerance to imatinib in patients (pts) with chronic myelogenous leukemia chronic phase (CML-CP) intolerant to imatinib: a retrospective analysis of safety
    Khoury, H. J.
    Goldberg, S. L.
    Mauro, M. J.
    Stone, R. M.
    Matloub, Y.
    Chen, T.
    Guilhot, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [38] Restrospective Multicenter Study Evaluating Efficacy and Safety of Dasatinib and Nilotinib in Patients with Imatinib-Resistant or -intolerant Chronic Myeloid Leukemia in Chronic Phase: Korean CML Working Party
    Lee, Jeong-Ok
    Kim, Inho
    Chung, Joo-Seop
    Kim, Yeo-Kyeoung
    Yhim, Ho-Young
    Kim, Dae-Young
    Do, Young-Rok
    Seong, Chu-Myong
    Nam, Seung-Hyun
    Kim, Sung-Hyun
    Lee, Jae-Hoon
    Park, Jinny
    Kim, Jin Seok
    Min, Yoo-Hong
    Sohn, Sang Kyun
    Joo, Young Don
    Bae, Sung-Hwa
    Oh, Sukjoong
    Zang, Dae Young
    Lee, Hong Ghi
    Yoon, Sung-Soo
    Park, Seonyang
    BLOOD, 2012, 120 (21)
  • [39] Phase II Clinical Trial Results of Dasatinib for Frontline Therapy in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP)
    Pemmaraju, Naveen
    Kantarjian, Hagop M.
    O'Brien, Susan
    Borthakur, Gautam
    Ravandi, Farhad
    Verstovsek, Srdan
    Daver, Naval G.
    Garcia-Manero, Guillermo
    DiNardo, Courtney D.
    Skinner, Jeff
    Konopleva, Marina
    Pierce, Sherry
    Jabbour, Elias
    Cortes, Jorge E.
    BLOOD, 2014, 124 (21)
  • [40] Phase II trial of dasatinib (DAS) in pediatric patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP).
    Gore, Lia
    Kearns, Pamela
    Lee, Maria Lucia
    De Souza, Carmino Antonio
    Bertrand, Yves
    Hijiya, Nobuko
    Stork, Linda C.
    Chung, Nack-Gyun
    Cardenas-Cardos, Rocio
    Saikia, Tapan
    Fagioli, Franca
    Seo, Jong-Jin
    Landman-Parker, Judith
    Lancaster, Donna
    Place, Andrew E.
    Rabin, Karen R.
    Sacchi, Mariana
    Swanink, Rene
    Zwaan, Michel
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345